Пять правил диетолога, чтобы живот не болел

1. Lacy B.E., Pimentel M., Brenner D.M., et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. 2. Stanghellini V., Chan F.K.L., Hasler W.L., et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380-1392. 3.Ивашкин В.Т., Маев И.В., Шептулин А.А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению синдрома раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74-95. 4. Vasant D.H., Paine P.A., Black C.J., et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-1240. 5. Hillestad E. M. R., van der Meeren A., Nagaraja B. H. et al. Gut bless you: The microbiota- gut-brain axis in irritable bowel syndrome. World J Gastroenterol. 2022;28(4):412-431. 6. Tack J., Camilleri M. New developments in the treatment of gastroparesis and functional dyspepsia. Curr Opin Pharmacol. 2018;43:111-117. 7. Gibson P.R., Halmos E.P., Muir J.G. Review article: FODMAPS, prebiotics and gut health-the FODMAP hypothesis revisited. Aliment Pharmacol Ther. 2020;52(2):233-246. 8. Feinle-Bisset C., Horowitz M. Dietary factors in functional dyspepsia. Neurogastroenterol Motil. 2006;18(8):608-18. 9. Duncanson K., Burns G., Pryor J., Keely S., Talley N.J. Mechanisms of Food-Induced Symptom Induction and Dietary Management in Functional Dyspepsia. Nutrients. 2021;13(4):1109. 10. Simrén M., Månsson A., Langkilde A.M., et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion. 2001;63(2):108-15. 11. Cozma-Petruţ A., Loghin F., Miere D., Dumitraşcu D.L. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients! World J Gastroenterol. 2017;23(21):3771-3783. 12. Общая характеристика лекарственного препарата и листок-вкладыш лекарственного препарата Но-шпа®. Регистрационное удостоверение: ЛП-№(002774)-(РГ-RU) от 06.10.2023 (для таблеток 40 мг), ЛП-№(001745)-(РГ-RU) от 05.10.2023 (для таблеток 80 мг). 13. Traserra S., Barber C., Alcalá-González L.G. et al. Evaluation of the mechanism of action of paracetamol, drotaverine, and peppermint oil and their effects in combination with hyoscine butylbromide on colonic motility: human ex-vivo study. Front Pharmacol. 2024;15:1384070. 14. Rai R.R., Nijhawan S. Comparative evaluation of efficacy and safety of drotaverine versus mebeverine in irritable bowel syndrome: A randomized double-blind controlled study. Saudi J Gastroenterol. 2021;27(3):136-143. 15. Rai R.R., Dwivedi M., Kumar N. Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: a randomized double-blind placebo-controlled study. Saudi J Gastroenterol. 2014;20(6):378-82. 16. Eder P., Kowalski P., Mastalerz-Migas A. et al. Self-Medication with Drotaverine among Patients with Common Abdominal Symptoms and Treatment Efficacy from the Perspectives of Patients and General Practitioners-An Observational, Retrospective, Cross-Sectional Study Using Real-World Data. J Clin Med. 2022;11(11):3156. 17. Bijkerk C.J., de Wit N.J., Muris J.W., et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154. 18. McRorie J.W. Jr, McKeown N.M. Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber. J Acad Nutr Diet. 2017;117(2):251-264. 19. Nanayakkara W.S., Skidmore P.M.L., O’Brien L., et al. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol. 2016;9:131-42. 20. Staudacher H.M., Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66(8):1517-1527.